Back to top
more

Novavax (NVAX)

(Real Time Quote from BATS)

$14.40 USD

14.40
1,169,026

-0.28 (-1.91%)

Updated Oct 3, 2024 10:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Translate Bio, Sanofi to Jointly Develop Coronavirus Vaccine

by Zacks Equity Research

Translate Bio (TBIO) gains on collaboration with Sanofi for a mRNA vaccine development for COVID-19.

Novavax Rallies as Influenza Vaccine Meets All Goals in Study

by Zacks Equity Research

Novavax's (NVAX) NanoFlu, the influenza vaccine candidate for adults aged 65 years and older, meets all the primary and secondary endpoints in late-stage study. Shares rise.

Biotech Stock Roundup: HOTH & IMV to Develop Coronavirus Vaccines, & More

by Zacks Equity Research

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

Company News for Mar 25, 2020

by Zacks Equity Research

Companies in the news are: NVAX, GSAT, INFO, GNW

Aytu BioScience to Issue Coronavirus Rapid Test in North America

by Zacks Equity Research

Aytu BioScience (AYTU) expands the right to distribute and commercialize the COVID-19 IgG/IgM rapid test across the United States, Canada and Mexico. Stock jumps.

Hoth Surges on Collaboration With Voltron for COVID-19 Vaccine

by Zacks Equity Research

Hoth (HOTH) soars following a joint venture with Voltron Therapeutics for a vaccine for COVID-19.

Axsome Expedites Completion Timeline of AD Study on AXS-05

by Zacks Equity Research

Axsome (AXSM) speeds up the evaluation time of AXS-05 under the phase II/III ADVANCE-1 study for Alzheimer's disease agitation to ensure safety of patients amid the COVID-19 pandemic.

Gilead's HCV Drug Epclusa Gets FDA Nod for Expanded Age Group

by Zacks Equity Research

The FDA approves Gilead's (GILD) sNDA for Epclusa to treat chronic hepatitis C infection in children aged six years and above or weighing at least 17 kg.

Emergent (EBS) to Help Vaxart Develop Coronavirus Vaccine

by Zacks Equity Research

Emergent BioSolutions (EBS) teams up with Vaxart to support development of the latter's oral vaccine candidate for treating coronavirus disease.

The Zacks Analyst Blog Highlights: Moderna, Novavax and Regeneron Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Novavax and Regeneron Pharmaceuticals

Sreoshi Bera headshot

5 Low-Beta Stocks to Tackle Coronavirus-Led Market Volatility

by Sreoshi Bera

The current volatility in equity market calls for investment in these five low-beta stocks.

Top Ranked Momentum Stocks to Buy for March 19th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 19th

Is Novavax (NVAX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (NVAX) Outperforming Other Medical Stocks This Year?

Tirthankar Chakraborty headshot

Hopes of a COVID-19 Vaccine Buoy Drug Makers: 3 Solid Buys

by Tirthankar Chakraborty

Shares of Moderna soared higher after the company dosed a patient with a vaccine against the novel coronavirus in the Phase 1 study. This, calls for investing in companies racing to develop a vaccine against COVID-19

Madeleine Johnson headshot

These 10 Drug Companies are Testing a Coronavirus Vaccine

by Madeleine Johnson

As the coronavirus pandemic continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

Ekta Bagri headshot

Biotech Sector in Focus as Coronavirus Spreads Panic

by Ekta Bagri

The outbreak of COVID-19 has brought the volatile biotech sector under the spotlight as both large and small companies rush to develop treatments and vaccines to combat this pandemic.

Emergent (EBS) Begins Development of Treatments for COVID-19

by Zacks Equity Research

Emergent (EBS) starts developing two plasma-derived product candidates for the treatment and prevention of coronavirus disease.

Kinjel Shah headshot

3 Small Biotechs Provide Coronavirus Drug Development Updates

by Kinjel Shah

Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.

Novavax (NVAX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of -4.63% and 120.95%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More

by Zacks Equity Research

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

Emergent BioSolutions Collaborates for Coronavirus Vaccine

by Zacks Equity Research

Emergent BioSolutions' (EBS) collaborates with Novavax to support production of the latter's coronavirus vaccine and advance it to clinical stage development.

Sriparna Ghosal headshot

3 MedTech Stocks to Rebound After Coronavirus-Led Recoil

by Sriparna Ghosal

As the coronavirus chaos continues to rise, MedTech firms have been witnessing a spike in demand for protective respiratory equipment.

5 Drug Makers to Gain From Coronavirus Outbreak

by Zacks Equity Research

Drug makers globally are working on developing therapies and vaccines for coronavirus. Here are five stocks that are currently in focus.

Kinjel Shah headshot

Trump Asks Pharma Firms to Step Up Coronavirus Vaccine Work

by Kinjel Shah

President Donald Trump asks pharmaceutical companies working on making vaccines or treatments for coronavirus to accelerate development.

Is Novavax (NVAX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (NVAX) Outperforming Other Medical Stocks This Year?